Precision Diagnostics: How a San Diego Lab Turned Urine Drug Tests Into a $96 Million False Claims Scheme

Precision Diagnostics LLC, a San Diego-based toxicology laboratory, agreed to pay $96 million to resolve allegations that it violated the False Claims Act and the Anti-Kickback Statute by paying remuneration to substance abuse treatment providers in exchange for urine drug testing referrals, then submitting claims to Medicare for tests that were not medically necessary and had not been ordered by treating physicians with genuine clinical intent.DOCUMENTED

The resolution is one of the largest involving a clinical toxicology laboratory in the period following the explosive growth of urine drug testing billing under federal health programs. Prosecutors and regulators have identified laboratory-to-treatment-provider kickback arrangements as a dominant vector of Medicare fraud in the addiction treatment sector, with multiple national enforcement sweeps targeting similar patterns across dozens of states.REVIEWED

The Kickback Arrangements

The complaint allegations describe Precision Diagnostics using multiple forms of remuneration to secure and maintain specimen referral relationships with substance abuse treatment centers, sober living facilities, and outpatient drug treatment programs. The arrangements included processing equipment loans — where Precision provided point-of-care testing devices to referring facilities at no charge — as well as payments characterized as medical director fees, consulting agreements, and specimen collection processing charges that exceeded fair market value for any legitimate service provided.DOCUMENTED

Federal anti-kickback law prohibits offering, paying, soliciting, or receiving remuneration to induce or reward the referral of items or services covered by federal health programs, including laboratory testing billed to Medicare and Medicaid. The law includes a specific safe harbor for equipment loans and processing agreements, but regulators found that Precision's arrangements were structured to provide value contingent on referral volume rather than to compensate genuinely for services provided — placing the arrangements outside the safe harbor's protection.REVIEWED

The Testing Panels and Billing Patterns

Medicare covers urine drug testing when it is medically necessary and ordered by a treating physician for a documented clinical purpose. The complaint alleges that Precision Diagnostics routinely billed for large confirmatory drug testing panels — which carry substantially higher reimbursement rates than presumptive immunoassay screening — regardless of whether a physician had reviewed the initial screening result and determined that confirmatory testing was clinically warranted for specific substances detected.DOCUMENTED

Confirmatory testing using mass spectrometry-based methods can identify specific drug compounds and quantify their concentration in a specimen, and carries per-substance billing codes that generate substantially higher Medicare reimbursement than the flat-rate immunoassay screens used for initial specimen evaluation. The billing model incentivized maximizing the number of confirmatory codes submitted per specimen regardless of clinical necessity, because reimbursement grew with the number of analytes confirmed rather than being tied to any particular treatment decision the results were intended to inform.REVIEWED

Treatment providers received benefits calibrated to the number of specimens they sent, not to the quality of the treatment relationship or to any legitimate service the laboratory provided in return.

The Qui Tam Relator

The federal investigation was initiated in part by a complaint filed under the False Claims Act's qui tam provisions, which allow private individuals with knowledge of fraud against the government to file sealed complaints on behalf of the United States and share in any recovery. The relator in this case was identified in court records as a former sales representative for a competing laboratory who had direct knowledge of Precision's referral relationships and billing practices.DOCUMENTED

Qui tam cases in the laboratory testing sector have generated significant recoveries over the past decade, driven largely by former employees and competitors with firsthand visibility into referral arrangements that are not visible from Medicare claims data alone. The pattern of substance abuse treatment laboratory fraud — in which the referring facility receives value from the lab while the lab bills federal programs for tests with no genuine clinical basis — has been the subject of multiple national enforcement initiatives, with individual recoveries ranging from a few hundred thousand dollars to settlements exceeding $100 million.REVIEWED

Civil Resolution and Exclusion

The settlement resolves the civil False Claims Act allegations and does not constitute an admission of liability by Precision Diagnostics. As part of the resolution, the laboratory entered into a Corporate Integrity Agreement with the Department of Health and Human Services Office of Inspector General, requiring independent review of billing practices, compliance training for all billing personnel, and mandatory reporting obligations for a period of five years following the effective date of the agreement.DOCUMENTED

Individuals with knowledge of similar arrangements between clinical laboratories and treatment programs are encouraged to contact Watchdog Journal's secure tip channel at /tips, or to consult with a qui tam attorney about potential whistleblower options under the False Claims Act.

Sector Pattern and Enforcement Context

The Precision Diagnostics resolution reflects a sustained period of federal enforcement against toxicology laboratories that built their business models around kickback-funded referral relationships with substance abuse treatment providers. The intersection of the opioid crisis and the expansion of urine drug testing as a clinical and billing category created conditions in which laboratories competed aggressively for referral relationships, and some used financial arrangements — including free equipment, above-market processing fees, and direct payments structured as medical director or consultation agreements — to secure exclusive specimen relationships with treatment programs. The federal government has prosecuted both laboratories and the treatment program operators who accepted payments in this category, with criminal charges following civil resolutions in several high-profile cases. Individuals with knowledge of similar arrangements between laboratories and treatment facilities are encouraged to contact the HHS OIG hotline or a qui tam attorney.

Healthcare providers and laboratory professionals who become aware of kickback arrangements in the laboratory testing space face both an ethical obligation to report and a potential financial incentive to do so under the False Claims Act's qui tam provisions. The OIG maintains a confidential fraud hotline that accepts tips from individuals who wish to report concerns without filing a formal qui tam complaint. Those who do file qui tam complaints should do so with the assistance of an attorney who specializes in healthcare fraud to ensure the complaint is filed correctly and the potential relator's rights are protected from the outset of the proceeding.

Have documents relevant to this story? Reach us through our tips channel.